




Akoya's 2nd Annual Spatial Day

December 15, 2022



Disclaimer

Cautionary Note Regarding Forward-Looking Statements

This presentation includes express and implied “forward-looking statements.” In some cases, you can identify forward-looking statements by terms such as “anticipate,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “will,” “would,” “should,” “could,” “can,” “predict,” “potential,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These statements may relate to our strategic plans or objectives, revenues or earnings projections, or other financial items. By their nature, these statements are subject to numerous uncertainties, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we, nor any other person, assumes responsibility for the accuracy and completeness of these statements. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

Market Industry Data

Projections, estimates, industry data and information contained in this presentation, including the Company’s general expectations and market position and market opportunity, are based on information from third-party sources and management estimates. Although the Company believes that its third-party sources are reliable, the Company cannot guarantee the accuracy or completeness of its sources. The Company’s estimates are derived from third-party sources, publicly available information, the Company’s knowledge of its industry and assumptions based on such information and knowledge. The Company’s estimates have not been verified by any independent source. All of the projections, estimates, market data and industry information used in this presentation involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. In addition, projections, estimates and assumptions relating to the Company’s and its industry’s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including, but not limited to, those described above, that could cause future performance to differ materially from the Company’s expressed projections, estimates and assumptions or those provided by third parties.

Welcome & Introduction



Brian McKelligon

CEO, Akoya Biosciences



Spatial Day Agenda

Welcome & Introduction

Brian McKelligon, Akoya Biosciences

New Products in Discovery & Translational Spatial Biology

Niro Ramachandran, Ph.D., Akoya Biosciences

Oliver Braubach, Ph.D., Akoya Biosciences

Guest Speakers:

Elizabeth Neumann, Ph.D., UC Davis

Arutha Kulasinghe, Ph.D., University of Queensland

Q&A Roundtable Hosted by Niro Ramachandran

Akoya's Clinical Vision

Gavin Gordon, Ph.D., Akoya Biosciences

Guest Speakers:

Laura Esserman, M.D., M.B.A., UCSF

Scott Rodig, M.D., Ph.D., Dana-Farber, Brigham & Women's & Harvard

Manuel Salto-Tellez, M.D., Queen's University Belfast & ICR

Q&A Roundtable Hosted by Gavin Gordon


Closing Remarks

Brian McKelligon, Akoya Biosciences

Q&A


Akoya is Leading the Spatial Biology Revolution

Transforming Discovery to Diagnostics



Best-in-class platform requirements

Fastest, multiomic, single-cell imaging with subcellular resolution on whole slide



Complete end-to-end solutions

Instruments, reagents, software & services



Established market leader with largest installed base

860+ instruments installed worldwide




Greatest number of high-impact publications

690+ total publications


Driving Towards a Deeper Understanding of Biology

Advancing Next Generation Tissue Analysis



Understanding disease progression & response to therapy requires UNBIASED mapping of tissue architecture


Current Tissue Analysis Methods Migrate to Spatial



Current tissue analysis methods deliver no or very limited spatial information




Spatial phenotyping



Understanding biomarkers in tissue context


Akoya's Industry Leading Spatial Platform

High-plex and High-throughput Protein & RNA Analysis



Akoya is Transforming Tissue Analysis


Mapping Whole Tissue Unlocks an Understanding of Disease Progression & Response to Therapy



The LOCATION of key cell types, proteins & transcripts drives tumor activity & immune response

Complete Solutions – From Discovery to Validation to Clinical


Driving Application Expansion & System Utilization



Largest & Rapidly Growing Installed Base

Adoption Across Discovery, Translational & Clinical Markets

Installed base of **863** instruments



229
PhenoCyclers




83
Phenolmager
Fusions



551
Phenolmager HTs,
Mantras & Vectras

Accelerating & Market Leading Publication Volume


Spatial Biology is Driving Major Discoveries Across Multiple Therapeutic Areas



*As of September 30, 2022

Immediate Opportunity in Discovery & Translational Markets with Clinical Rapidly Emerging

Estimated Total Addressable Market (TAM) ~ \$14B




Akoya is meeting customer & market segment **requirements** to drive market expansion

Drivers of Spatial Biology Market Growth Over Next 5 Years

DeciBio Projects < 10% of TAM to be Realized by 2027*

- Spatial biology market will grow 30% annually in the next 5 years
- Translational & clinical research to make up the largest market segment
- Routine clinical dx expected to be the fastest growing market segment
- Multi-plex immunofluorescence (mIF) a key technology growth driver

Spatial Biology Market Trends




Akoya's Strategic Priorities

Drive Workflow Improvements & Success in Translational Market Drives Clinical Success



Accelerate Pull Through

- Expand menu of applications
- Platform improvements drive throughput
- Streamline data analysis & time to answer



Accelerate Clinical Journey

- Drive translational adoption - Advanced Biopharma Solutions (ABS) CLIA Lab
- Deliver on the Acrivon CDx
- Expand & deliver on high value partnerships



New Product Introductions




Niro Ramachandran, Ph.D.

CBO, Akoya Biosciences



Evolution of Customer Needs in Spatial Biology

Emerging Need for Simplicity



Path Towards Simplest Spatial Biology Solutions



Rapid menu expansion enabling more ready to use assays



Faster workflows to meet project needs



Flexible data analysis to serve every user need

PhenoCycler-Fusion



2.0

Upgrading to the PhenoCycler-Fusion 2.0

PhenoCycler-Fusion 1.0



PhenoCycler-Fusion 2.0



Content Menu	A-la-carte proteins	Panel-based protein & RNA
Panel Design	Optimization required	Ready-to-use
Throughput	~10 samples / week	~20 samples / week
Analysis	Real-time data compression, Akoya-provided	Data compression & rapidly growing ecosystem

PhenoCycler-Fusion 2.0 enables menu expansion, faster workflow, scaled experiments & improved analysis

RNAscope HiPlex v2 on PhenoCycler-Fusion 2.0

Extending Our RNA Solution Portfolio Through a Strategic Partnership with ACD




The leader in single-cell spatial proteomics with whole-slide imaging at single cell resolution



The gold standard in low to mid-plex spatial *in situ* assays based on proven RNAscope™ technology


RNAscope HiPlex v2 complements Akoya's solution & **empowers our customers with:**

- A direct RNA detection technology
- Automated 12-plex RNA configuration
- Sample-to-data within 24 hours
- Expansion into new research areas
- Custom and/or defined panel flexibility



*For Research Use Only. Product Not Yet Commercially Available, Subject to Change

Automated 12-plex RNAscope HiPlex v2 Assay



A Suite of RNA Solutions with PhenoCycler-Fusion 2.0

Leveraging *In Situ* Cycling to Deliver a Growing Suite of Transcriptomics Solutions



ACD's RNAscope HiPlex v2

Established standard with >5,800 publications

Targeted applications or validation studies

Commercial rollout 1H '23 on PhenoCycler-Fusion 2.0



Akoya's Proprietary RNA Technology

High-plex RNA & multiomic (RNA & protein) capability

Unbiased biomarker discovery experiments

Commercially available 2H '23 on PhenoCycler-Fusion 2.0

RNA or Protein?
Discovery or Signatures?


PD-1, PD-L1, FoxP3,
CD3, CD8, CD4,
CD20, CD68, CD163,
PanCK, SOX10, S100

PD-1, PD-L1, FoxP3,
CD3, CD8, CD4,
CD20, CD68, CD163,
PanCK, SOX10, S100

Introducing **PhenoCode**

A Premier Brand of Spatial Phenotyping Panels & Assays

Simplifying Solutions – Discovery to Validation to Clinical



PhenoCode™ Panels

Product

PhenoCode™ Discovery Panels

PhenoCode™ Signature Panels

Chemistry

Protein, RNA, or Multiomic

Protein


Workflow

PhenoCycler®

PhenoImager®



What is a Spatial Signature?




Enabling Panel-Based Immuno-Oncology Spatial Solutions



PhenoCode™ **Signature Panels**

Commercial rollout of first five panels in 1H '23



Dual-Slide Capability with PhenoCycler-Fusion 2.0

2X slide automation = 2X throughput / week

More samples = More cells = More data points = More significance = More discoveries

Faster sample to data

Parallel processing of 2 slides

Foundational to increase reagent pull through


Enables higher plex protein, RNAscope automation & multiomic content

Commercial rollout through field
upgrades beginning 1H '23



PhenoCycler-Fusion 2.0 slide carrier

Framework for Comprehensive Spatial Phenotyping




Powerful Tools Required for Diverse Image Analysis Needs




DISCOVERY




Machine Driven Clustering



Cell Neighborhoods



Bioinformatics Driven




Flexible


TRANSLATIONAL




User Guided AI



Margin Analysis




Pathology Driven



Fit-for-purpose

Terabyte Size Files Prohibitive for Flexible Data Management

1 TB

[illegible]

```


101011100110000110101110000010
110010111110110000001101011101
10110000011110001011000010101
0100001100

```


Few GBs

Akoya's
proprietary file
compression
algorithm

Software Adoption Depends on Flexible Data Analysis



Software Adoption Depends on Flexible Data Analysis



Data Ecosystem Expansion Across Akoya's Workflows

Before

- Unconnected solutions
- Complex pre-analysis image processing



Now

- Data standardization through a growing software ecosystem
- Accessibility to cutting-edge analysis & simplified on-instrument image processing with file compression

Flexible Open Source



QuPath

Machine Learning & AI



PathAI

VISIO  PHARM®

indica labs 
QUANTITATIVE PATHOLOGY

Powerful High-plex Analysis in the Cloud

ENABLE 

Leading Analysis Service Providers


 OracleBio

Software partnerships provide
economical, flexible & comprehensive
data analysis solutions



Faster, Scalable & Flexible Workflow to Drive Pull Through

INSTRUMENT UPGRADE



THROUGHPUT

2X INCREASE



NEW CONSUMABLE PRODUCT

**PhenoCode
Signature Panels**

PANEL DEVELOPMENT & OPTIMIZATION TIME

3X REDUCTION



PARTNERSHIPS




RNA for Targeted Validation



VISIO PHARM®



Flexible Analysis Solutions



PhenoCode™ Signature Panels



Oliver Braubach, Ph.D.


Director of Applications, Akoya Biosciences




Spatial Phenotyping & the Era of Spatial Biomarkers

“Spatial Biomarkers” Harbor Enormous Potential for Immunotherapy Patient Stratification

The *SpatialScore* is a **spatial signature** around interactions between CD4⁺T cells, Tregs, & tumor cells



A low *SpatialScore* correlated strongly with a positive response pembrolizumab & vice versa




**Mining multiplex data informs about tumor biology & mechanisms
of immune & clinical response that can guide drug development & patient stratification**

Graph Neural Network (GNN) Models to Capture Complex Spatial Relationships

Graph neural networks

Spatial graphs to relate human-interpretable features (HIFs) to make predictions that incorporate tissue spatial orientation



Key terminology

Nodes – Used to describe biological structures within tissue (e.g., cells)

Edges – Used to describe relationships between nodes (e.g., spatial proximity)

Graph - a set of nodes & edges

Predictions are qualitatively traceable to biologically relevant spatial structures

Ability to analyze & correlate hundreds of markers simultaneously, in contrast to a 'per-marker' analysis

Requires tissue & cell segmentation & specification but learns from spatial organization


May be susceptible to bias & errors in underlying tissue & cell identification model

Example - Spatial Phenotypes & Clusters


Unbiased Identification of Spatial Phenotypes Defined by Cell Type Composition & Spatial Arrangement

Features and cell locations derived from inForm segmentation & clustered into spatial phenotypes

mIF Features





mIF GNN




Models incorporate spatial organization & cell-level mIF features

Analysis of spatial phenotypes identify cell types that drive categorization

Spatial phenotypes



Interpretability




In this example, phenotype 2 is highly enriched for cell types 3-6


Example – Unsupervised Predictive Analytics

Statistical Correlation of Spatial Signatures to Outcomes or Other Clinically Relevant Features

Analysis of standard features extracted from image analysis platform did not reveal significantly predictive biomarkers



Whereas PathAI's GNN-derived stratification identified signatures with predictive value



PhenoCode™ Signature Panels

Decode the Science of Response to Combination Therapy



Relevant

Answer the most pertinent questions to interrogate the TME



Flexible

Answer your novel question by adding a marker of choice




Fast

Speed up Spatial Signature development by 3X




Scalable

Seamlessly translate discoveries into predictive biomarkers




Flexible Panels

Providing the Flexibility to Ask Your Specific Question



Flexibility to Answer a Myriad of Questions

Map Additional Phenotypes



CD4

Where are the Helper T cells?

PD-1

Are the T cells exhausted?

Ki67

Which cell types are proliferating?

CD20

Where are the B cells?

GrzB

Where are the activated immune cells?


?

Marker of choice for specific research question

Answer More Questions Quickly


Flexibility Allows for Easy Integration of One Additional Marker

IMMUNO-CONTEXTURE PANEL




CD8, CD68,
PD-L1, FoxP3,
PanCK

+





CD20

Where are the B cells in the TME?




“Hot” Tumor A
No signs of TLS
(low density B cells)




“Hot” Tumor B
Signs of TLS formation
(high density B cells)

IMMUNO-CONTEXTURE PANEL





CD8, CD68,
PD-L1, FoxP3,
PanCK

+





PD-1

Are the T cells exhausted?



PhenoCode™ Signature Panels Offer Excellent Reproducibility

Integration of Different Markers Does Not Impact Reproducibility






Panel 1: PD-1 Panel 2: CD20




PhenoCode™ Signature Panels Benchmarking

Workflow Efficiency with Gold-standard Performance


6-plex Immuno- Contexture



6-plex Immune Profile



Key Benefits: PhenoCode™ Signature Workflow



Guest Speaker



Elizabeth Neumann, Ph.D.

Assistant Professor of Chemistry

UC DAVIS
UNIVERSITY OF CALIFORNIA

Guest Speaker



Arutha Kulasinghe, Ph.D.

NHMRC Research Fellow and Group Leader
University of Queensland Diamantina Institute



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

Q&A Roundtable



Niro Ramachandran, Ph.D.
CBO, Akoya Biosciences



Elizabeth Neumann, Ph.D.
Assistance Professor of Chemistry
University of California Davis



Arutha Kulasinghe, Ph.D.
NHMRC Research Fellow and Group Leader
University of Queensland Diamantina Institute

Akoya's Clinical Vision



Gavin Gordon, Ph.D.

VP of Clinical Market Development, Akoya Biosciences





Akoya's Clinical Vision

Establish the standard for clinical protein multiplexing applications


Evolving to Realize Our Clinical Aspirations

Commercial



From life sciences tools company
to a medical company

Product



From imaging platform to
diagnostic platform

Market



From scientist to clinician

Akoya's Contribution to the Patient Journey

Key Opportunities Are in Diagnostic Pathology & Predictive Testing





Screening

Diagnosis



Treatment

Monitoring



Predictive

The Opportunity in Diagnostic Pathology

Multiplexing Preserves Tissue, Improves Diagnostic Accuracy & Improves Workflow Efficiency

Diagnosis




Today



Many slides for single marker IHC

Tomorrow





Single slide multiplexing

The Opportunity in Predictive Testing

Next-gen Spatial Signatures for Therapy Selection Will Improve Patient Outcomes

Today



OncoSignature Report

Patient, John
Date of birth: 27-Jan-1956
Ordering Physician: Dr A Test
Client: Global laboratories
Gender: Male
Report Number: LU2323
Report Date: 10-Dec-2024

AKOYA BIOSCIENCES

Results

Positive +

Clinical Interpretation

Positive: >5% positive cell expression for BM1 and >25% positive expression for BM2

Lab Director Comments:


May have a clinical response to and benefit from ACR-238 regardless of prior line(s) of therapy^{1,2}

Reference

- PD-L1 cutoff approved by FDA for Tecentria, Keytruda, and OPDIVO: https://www.fda.gov/oc/ohrt/tecentria_prescribing.pdf (05/2020); https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf (06/2020); <https://packagelabels.bms.com/opdivo.pdf> (04/2020)
- PD-L1 cutoff approved by FDA for Tecentria: https://www.fda.gov/oc/ohrt/tecentria_prescribing.pdf (05/2020)

Multiplexing w/individual marker reporting (e.g. PD-L1 + TILs)

Tomorrow



OncoSignature Report

Patient, John
Date of birth: 27-Jan-1956
Ordering Physician: Dr A Test
Client: Global laboratories
Gender: Male
Report Number: LU2323
Report Date: 10-Dec-2024

AKOYA BIOSCIENCES

Results

Positive +

Clinical Interpretation

Positive: >5% positive cell expression for BM1 and >25% positive expression for BM2


Lab Director Comments:

May have a clinical response to and benefit from ACR-238 regardless of prior line(s) of therapy^{1,2}

Reference

- PD-L1 cutoff approved by FDA for Tecentria, Keytruda, and OPDIVO: https://www.fda.gov/oc/ohrt/tecentria_prescribing.pdf (05/2020); https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf (06/2020); <https://packagelabels.bms.com/opdivo.pdf> (04/2020)
- PD-L1 cutoff approved by FDA for Tecentria: https://www.fda.gov/oc/ohrt/tecentria_prescribing.pdf (05/2020)

Spatial phenotyping w/binary reporting



Predictive


Clinical Market Rapidly Emerging

Estimated Total Addressable Market (TAM) ~ \$14B



Significant Unmet Medical Need in Immunotherapy

JAMA Publication Highlights Spatial Phenotyping as a Superior Approach¹



What is next?

Ideal predictive power
Response to immunotherapy in solid tumors

High	Low
>80%	<5%

Tumor Mutational Burden (TMB)

Limited predictive power
Response to immunotherapy in solid tumors³

High TMB	Low TMB
~40%	~20%

PDL1 IHC

Limited predictive power
Response to immunotherapy in solid tumors²

PDL1 +	PDL1 -
~40%	~13%
True Positive	False Negative

¹ Lu S, Stein JE, Rimm DL, et al, JAMA Oncology 2019;5(8):1195–1204

² Diggs and Hsueh Biomarker Research (2017) 5:12;

³ Hendriks LE, et.al.. Transl Lung Cancer Res. 2018;7(6):647-660

Pharma Partnerships Key to Developing Clinical Market

Engage Immunotherapy Developers to Support Translational & Clinical Research in Oncology

PD-1/L1 mAb Clinical Trial Landscape

Published on February 10, 2022


Sources: CRI, CRI Analytics, and Clinicaltrials.gov



CANCER
RESEARCH
INSTITUTE

The Anna-Maria Kellen
Clinical
Accelerator

Total **5,683** interventional trials as of December, 2021



Explosion of PD-1/L1 combination trials since 2017, but approval rate remains low (~1%)

- Pharma shifting focus to combination therapies in I/O
- Significant unmet need for biomarkers to stratify patients

Akoya's platforms and CLIA lab services support development of clinically validated biomarker signatures that enrich for patient response

CLIA-Certified Advanced Biopharma Solutions (ABS) Lab



CLIA-certified Laboratory for Scalable & Flexible Development

- Multidisciplinary team for each stage of CDx development
 - Scientists, pathologists, bioinformatics, regulatory experts, program managers & operations
- Biomarker discovery & validation
- Assay development, validation & deployment
- Designed to meet analytical & clinical performance criteria
- Early phase assay transfer: IHC or IF to IVD-ready platforms
- Clinical trial site in combination with our network of CRO partners



The Future is Now: Spatial Precision Medicine is HERE

Akoya announces
partnership:

First-in-class spatial signature CDx



Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon's Proprietary OncoSignature® Test into a Companion Diagnostic

June 28, 2022

The OncoSignature® test developed based on Acrivon's AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers

The OncoSignature® test will run on Akoya's Phenolmager™ Solution

06.22.2022

Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368

--Pioneering trial will be using a first-of-its-kind OncoSignature® companion diagnostic to identify and treat patients that are predicted most likely to benefit from treatment--


--OncoSignature®-positive patients will receive ACR-368 monotherapy in a single-arm Phase 2 study and OncoSignature®-negative patients will receive ACR-368 in combination with low-dose gemcitabine in a concurrent Phase 1b/2 study--

--ACR-368 is a DNA Damage Response (DDR) inhibitor that will be evaluated at the recommended Phase 2 dose based on extensive clinical safety and efficacy data, including previously demonstrated durable single-agent activity and complete responses in platinum-resistant ovarian cancer, as well as other high unmet need solid tumors--



OncoSignature® CDx - New Era of Precision Medicine

First-of-its-kind Spatial Signature CDx Assay to Identify Patients for a Targeted Oncology Agent



CDx assay developed on Phenolmager HT in Akoya CLIA lab

OncoSignature® test, a spatial signature CDx assay

Patient screened using OncoSignature® test to identify responders to ACR-368

Pending FDA approval, results of OncoSignature® test used to assign therapy

Akoya & Acrivon will co-develop, validate & exclusively commercialize the OncoSignature® test

Spatial Phenotyping Through Akoya ABS Lab Services

Biopharma Partnerships Drive Translational Market Growth & Clinical Market Entry

Standardized on Phenomager HT for immuno-oncology biomarkers

Rapid expansion of work through ABS



Audit and Validation

Multiple clinical trials
Biomarker discovery programs



CLIA certification enables enrollment studies

2019

2020

2021

2022

Advancing Akoya's First Mover Advantage

Translating Discoveries to the Clinic & Building the Foundations for Diagnostics



Guest Speaker



Laura Esserman, M.D., M.B.A.

Director of Carol Franc Buck Breast Care Center
Surgeon & Breast Cancer Oncology Specialist



University of California
San Francisco

Guest Speaker



Scott Rodig, M.D., Ph.D.

Director of the Tissue Biomarker Laboratory of the Center for Immuno-Oncology at Dana-Farber Cancer Institute

Diagnostic Pathologist, Brigham & Women's Hospital

Professor of Pathology, Harvard Medical School



Guest Speaker



Manuel Salto-Tellez, M.D.

Chair of Molecular Pathology at Queen's University Belfast

Professor on Integrative Pathology at the Institute for Cancer Research



Q&A Roundtable



Gavin Gordon, Ph.D.

VP of Clinical Market Development, Akoya Biosciences



Laura Esserman, M.D., M.B.A.

Surgeon & Breast Cancer Oncology Specialist, UCSF



Scott Rodig, M.D., Ph.D.

Investigational & Diagnostic Pathologist, Dana-Farber & Brigham & Women's; Professor of Pathology, Harvard



Manuel Salto-Tellez, M.D.

Chair & Professor of Molecular Pathology, Queen's University Belfast & ICR

Closing Remarks



Brian McKelligon

CEO, Akoya Biosciences



Catalyzing Discovery and Improving Patient Care

